The FDA issued regulatory approval to Covidien for the company’s LigaSure Maryland vessel sealer/divider that can be used in both open and laparoscopic surgeries. The company is also reporting that it completed all necessary steps to receive the CE Mark required for European distribution.
The LigaSure Maryland combines a Maryland dissector for separating tissue, an atraumatic tissue grasper, and cold surgical scissors into one device for efficient procedures with fewer instrument changes.
LigaSure vessel sealing technology is powered by the ForceTriad™ energy platform, controlled by TissueFectTM sensing technology, which monitors changes in tissue 3,333 times per second and adjusts energy output accordingly to deliver the appropriate amount of energy for the desired tissue effect. LigaSure vessel sealing uses the body’s own collagen and elastin to create a permanent fusion zone. Covidien’s proprietary technology can fuse vessels up to and including 7 mm, lymphatics, tissue bundles and pulmonary vasculature.
The LigaSure Maryland jaw device comes in three lengths. Covidien plans to roll out the 37 cm version to select customers early in 2014 and launch the shorter 23 cm and longer 44 cm options later this year. Covidien designed the LigaSure Maryland jaw device for use in minimally invasive procedures including urologic, vascular, thoracic and thoracoscopic, and gynecologic procedures where ligation and division of the vessels is performed.